Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Neoplasms of the CNS

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 67 articles:
HTML format
Text format



Single Articles


    September 2018
  1. SONG X, Shu XH, Wu ML, Zheng X, et al
    Postoperative resveratrol administration improves prognosis of rat orthotopic glioblastomas.
    BMC Cancer. 2018;18:871.
    PubMed     Text format     Abstract available


  2. MIKKELSEN VE, Stensjoen AL, Granli US, Berntsen EM, et al
    Angiogenesis and radiological tumor growth in patients with glioblastoma.
    BMC Cancer. 2018;18:862.
    PubMed     Text format     Abstract available


    July 2018
  3. DU D, Yuan J, Ma W, Ning J, et al
    Clinical significance of FBXO17 gene expression in high-grade glioma.
    BMC Cancer. 2018;18:773.
    PubMed     Text format     Abstract available


  4. ZHONG C, Chen Y, Tao B, Peng L, et al
    LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway.
    BMC Cancer. 2018;18:722.
    PubMed     Text format     Abstract available


    May 2018
  5. WANG Y, Guan G, Cheng W, Jiang Y, et al
    ARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL.
    BMC Cancer. 2018;18:599.
    PubMed     Text format     Abstract available


  6. MARTINI M, de Pascalis I, D'Alessandris QG, Fiorentino V, et al
    VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
    BMC Cancer. 2018;18:553.
    PubMed     Text format     Abstract available


  7. LEE C, Lee J, Choi SA, Kim SK, et al
    M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas.
    BMC Cancer. 2018;18:535.
    PubMed     Text format     Abstract available


  8. SCHULZE M, Hutterer M, Sabo A, Hoja S, et al
    Chronophin regulates active vitamin B6 levels and transcriptomic features of glioblastoma cell lines cultured under non-adherent, serum-free conditions.
    BMC Cancer. 2018;18:524.
    PubMed     Text format     Abstract available


  9. HEGGE B, Sjottem E, Mikkola I
    Generation of a PAX6 knockout glioblastoma cell line with changes in cell cycle distribution and sensitivity to oxidative stress.
    BMC Cancer. 2018;18:496.
    PubMed     Text format     Abstract available


    April 2018
  10. VOSOUGHI E, Lee JM, Miller JR, Nosrati M, et al
    Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.
    BMC Cancer. 2018;18:490.
    PubMed     Text format     Abstract available


  11. JIN J, Gao Y, Zhang J, Wang L, et al
    Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer.
    BMC Cancer. 2018;18:446.
    PubMed     Text format     Abstract available


  12. CHIO CC, Chen KY, Chang CK, Chuang JY, et al
    Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells.
    BMC Cancer. 2018;18:379.
    PubMed     Text format     Abstract available


  13. BOTTCHER MA, Held-Feindt J, Synowitz M, Lucius R, et al
    Modeling treatment-dependent glioma growth including a dormant tumor cell subpopulation.
    BMC Cancer. 2018;18:376.
    PubMed     Text format     Abstract available


  14. FATAI AA, Gamieldien J
    A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer.
    BMC Cancer. 2018;18:377.
    PubMed     Text format     Abstract available


    March 2018
  15. AABERG-JESSEN C, Sorensen MD, Matos ALSA, Moreira JM, et al
    Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas.
    BMC Cancer. 2018;18:270.
    PubMed     Text format     Abstract available


  16. RANJAN S, Quezado M, Garren N, Boris L, et al
    Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases.
    BMC Cancer. 2018;18:239.
    PubMed     Text format     Abstract available


    February 2018
  17. HAN Y, Yan LF, Wang XB, Sun YZ, et al
    Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
    BMC Cancer. 2018;18:215.
    PubMed     Text format     Abstract available


  18. SCHIMMEL WCM, Verhaak E, Hanssens PEJ, Gehring K, et al
    A randomised trial to compare cognitive outcome after gamma knife radiosurgery versus whole brain radiation therapy in patients with multiple brain metastases: research protocol CAR-study B.
    BMC Cancer. 2018;18:218.
    PubMed     Text format     Abstract available


  19. JIAO XD, Ding C, Zang YS, Yu G, et al
    Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report.
    BMC Cancer. 2018;18:206.
    PubMed     Text format     Abstract available


  20. TOTON E, Romaniuk A, Konieczna N, Hofmann J, et al
    Impact of PKCepsilon downregulation on autophagy in glioblastoma cells.
    BMC Cancer. 2018;18:185.
    PubMed     Text format     Abstract available


  21. MARITAZ C, Lemare F, Laplanche A, Demirdjian S, et al
    High-dose thiotepa-related neurotoxicity and the role of tramadol in children.
    BMC Cancer. 2018;18:177.
    PubMed     Text format     Abstract available


  22. AHN MJ, Lee K, Lee KH, Kim JW, et al
    Combination of anti-PD-1 therapy and stereotactic radiosurgery for a gastric cancer patient with brain metastasis: a case report.
    BMC Cancer. 2018;18:173.
    PubMed     Text format     Abstract available


  23. MOREN L, Perryman R, Crook T, Langer JK, et al
    Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.
    BMC Cancer. 2018;18:167.
    PubMed     Text format     Abstract available


  24. VASAIKAR S, Tsipras G, Landazuri N, Costa H, et al
    Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?
    BMC Cancer. 2018;18:154.
    PubMed     Text format     Abstract available


  25. LIU F, Huang J, Zhang L, Fan F, et al
    Screening for distress in patients with primary brain tumor using distress thermometer: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:124.
    PubMed     Text format     Abstract available


    January 2018
  26. EISEMANN T, Costa B, Strelau J, Mittelbronn M, et al
    An advanced glioma cell invasion assay based on organotypic brain slice cultures.
    BMC Cancer. 2018;18:103.
    PubMed     Text format     Abstract available


  27. CHOU SY, Yen SL, Huang CC, Huang EY, et al
    Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy.
    BMC Cancer. 2018;18:105.
    PubMed     Text format     Abstract available


  28. RICCIARDI GRR, Russo A, Franchina T, Schifano S, et al
    Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
    BMC Cancer. 2018;18:97.
    PubMed     Text format     Abstract available


  29. GOLDSMITH CS, Kim SM, Karunarathna N, Neuendorff N, et al
    Inhibition of p38 MAPK activity leads to cell type-specific effects on the molecular circadian clock and time-dependent reduction of glioma cell invasiveness.
    BMC Cancer. 2018;18:43.
    PubMed     Text format     Abstract available


  30. XIA L, Fang C, Chen G, Sun C, et al
    Relationship between the extent of resection and the survival of patients with low-grade gliomas: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:48.
    PubMed     Text format     Abstract available


  31. STRAUBE C, Scherb H, Gempt J, Kirschke J, et al
    Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma - the GlioCave study (NOA 17 - ARO 2016/3 - DKTK ROG trial).
    BMC Cancer. 2018;18:15.
    PubMed     Text format     Abstract available


    December 2017
  32. CHANG CH, Liu WT, Hung HC, Gean CY, et al
    Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells.
    BMC Cancer. 2017;17:905.
    PubMed     Text format     Abstract available


  33. CONDE M, Michen S, Wiedemuth R, Klink B, et al
    Chromosomal instability induced by increased BIRC5/Survivin levels affects tumorigenicity of glioma cells.
    BMC Cancer. 2017;17:889.
    PubMed     Text format     Abstract available


    November 2017
  34. YOMO S, Oguchi K
    Prospective study of 11C-methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment.
    BMC Cancer. 2017;17:713.
    PubMed     Text format     Abstract available


    October 2017
  35. TRAN LT, Lai HTM, Koriyama C, Uwatoko F, et al
    The association between high birth weight and the risks of childhood CNS tumors and leukemia: an analysis of a US case-control study in an epidemiological database.
    BMC Cancer. 2017;17:687.
    PubMed     Text format     Abstract available


    August 2017
  36. NOH MG, Oh SJ, Ahn EJ, Kim YJ, et al
    Prognostic significance of E-cadherin and N-cadherin expression in Gliomas.
    BMC Cancer. 2017;17:583.
    PubMed     Text format     Abstract available


    July 2017
  37. ZINDLER JD, Bruynzeel AME, Eekers DBP, Hurkmans CW, et al
    Whole brain radiotherapy versus stereotactic radiosurgery for 4-10 brain metastases: a phase III randomised multicentre trial.
    BMC Cancer. 2017;17:500.
    PubMed     Text format     Abstract available


  38. MIELE E, Po A, Begalli F, Antonucci L, et al
    beta-arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells.
    BMC Cancer. 2017;17:488.
    PubMed     Text format     Abstract available


    June 2017
  39. WIBROE M, Cappelen J, Castor C, Clausen N, et al
    Cerebellar mutism syndrome in children with brain tumours of the posterior fossa.
    BMC Cancer. 2017;17:439.
    PubMed     Text format     Abstract available


  40. HAYASHI N, Takahashi H, Hasegawa Y, Higuchi F, et al
    A nationwide multi-institutional retrospective study to identify prognostic factors and develop a graded prognostic assessment system for patients with brain metastases from uterine corpus and cervical cancer.
    BMC Cancer. 2017;17:397.
    PubMed     Text format     Abstract available


    May 2017
  41. TEYSSONNEAU D, Daste A, Dousset V, Hoepffner JL, et al
    Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.
    BMC Cancer. 2017;17:323.
    PubMed     Text format     Abstract available


    April 2017
  42. URUP T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, et al
    Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients.
    BMC Cancer. 2017;17:278.
    PubMed     Text format     Abstract available


  43. TRUBICKA J, Zemojtel T, Hecht J, Falana K, et al
    The germline variants in DNA repair genes in pediatric medulloblastoma: a challenge for current therapeutic strategies.
    BMC Cancer. 2017;17:239.
    PubMed     Text format     Abstract available


  44. LI MX, He H, Ruan ZH, Zhu YX, et al
    Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
    BMC Cancer. 2017;17:245.
    PubMed     Text format     Abstract available


    March 2017
  45. DALAN AB, Gulluoglu S, Tuysuz EC, Kuskucu A, et al
    Simultaneous analysis of miRNA-mRNA in human meningiomas by integrating transcriptome: A relationship between PTX3 and miR-29c.
    BMC Cancer. 2017;17:207.
    PubMed     Text format     Abstract available


  46. NARAYAN RS, Fedrigo CA, Brands E, Dik R, et al
    The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
    BMC Cancer. 2017;17:204.
    PubMed     Text format     Abstract available


  47. JENSEN SS, Petterson SA, Halle B, Aaberg-Jessen C, et al
    Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo.
    BMC Cancer. 2017;17:178.
    PubMed     Text format     Abstract available


    February 2017
  48. PANOSYAN EH, Lin HJ, Koster J, Lasky JL 3rd, et al
    In search of druggable targets for GBM amino acid metabolism.
    BMC Cancer. 2017;17:162.
    PubMed     Text format     Abstract available


  49. DEWAN R, Pemov A, Dutra AS, Pak ED, et al
    First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    BMC Cancer. 2017;17:127.
    PubMed     Text format     Abstract available


  50. LI Y, Li J, Woo YM, Shen Z, et al
    Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model.
    BMC Cancer. 2017;17:126.
    PubMed     Text format     Abstract available


  51. SHANNON S, Jia D, Entersz I, Beelen P, et al
    Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901.
    BMC Cancer. 2017;17:121.
    PubMed     Text format     Abstract available


  52. GERSEY ZC, Rodriguez GA, Barbarite E, Sanchez A, et al
    Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species.
    BMC Cancer. 2017;17:99.
    PubMed     Text format     Abstract available


    January 2017
  53. DENG X, Zheng Z, Lin B, Su H, et al
    The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
    BMC Cancer. 2017;17:42.
    PubMed     Text format     Abstract available


  54. RADES D, Janssen S, Dziggel L, Blanck O, et al
    A matched-pair study comparing whole-brain irradiation alone to radiosurgery or fractionated stereotactic radiotherapy alone in patients irradiated for up to three brain metastases.
    BMC Cancer. 2017;17:30.
    PubMed     Text format     Abstract available


  55. FROMBERG A, Rabe M, Oppermann H, Gaunitz F, et al
    Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells.
    BMC Cancer. 2017;17:3.
    PubMed     Text format     Abstract available


    December 2016
  56. YOMO S, Hayashi M
    Is upfront stereotactic radiosurgery a rational treatment option for very elderly patients with brain metastases? A retrospective analysis of 106 consecutive patients age 80 years and older.
    BMC Cancer. 2016;16:948.
    PubMed     Text format     Abstract available


    November 2016
  57. WONG ET, Timmons J, Callahan A, O'Loughlin L, et al
    Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.
    BMC Cancer. 2016;16:914.
    PubMed     Text format     Abstract available


  58. MUROTA Y, Tabu K, Taga T
    Requirement of ABC transporter inhibition and Hoechst 33342 dye deprivation for the assessment of side population-defined C6 glioma stem cell metabolism using fluorescent probes.
    BMC Cancer. 2016;16:847.
    PubMed     Text format     Abstract available


    October 2016
  59. OEHLKE O, Mix M, Graf E, Schimek-Jasch T, et al
    Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).
    BMC Cancer. 2016;16:769.
    PubMed     Text format     Abstract available


    April 2016
  60. GRAMATZKI D, Roth P, Felsberg J, Hofer S, et al
    Chemotherapy for intracranial ependymoma in adults.
    BMC Cancer. 2016;16:287.
    PubMed     Text format     Abstract available


    January 2016
  61. AKIMOTO J, Fukuhara H, Suda T, Nagai K, et al
    Clinicopathological analysis in patients with neuroendocrine tumors that metastasized to the brain.
    BMC Cancer. 2016;16:36.
    PubMed     Text format     Abstract available


  62. CHOI SA, Kwak PA, Kim SK, Park SH, et al
    In vivo bioluminescence imaging for leptomeningeal dissemination of medulloblastoma in mouse models.
    BMC Cancer. 2016;16:723.
    PubMed     Text format     Abstract available


  63. SCHORB E, Finke J, Ferreri AJ, Ihorst G, et al
    High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma-a randomized phase III trial (MATRix).
    BMC Cancer. 2016;16:282.
    PubMed     Text format     Abstract available


  64. NIIBE Y, Nishimura T, Inoue T, Karasawa K, et al
    Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
    BMC Cancer. 2016;16:659.
    PubMed     Text format     Abstract available


  65. FLECKENSTEIN J, Petroff A, Schafers HJ, Wehler T, et al
    Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    BMC Cancer. 2016;16:348.
    PubMed     Text format     Abstract available


  66. KIM S, Nam SJ, Kwon D, Kim H, et al
    MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
    BMC Cancer. 2016;16:363.
    PubMed     Text format     Abstract available


  67. ANGELINO G, De Pasquale MD, De Sio L, Serra A, et al
    NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications.
    BMC Cancer. 2016;16:512.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: